VERICEL CORPORATION Earnings Per Share (Diluted)
VERICEL CORPORATION (VCEL) reported Earnings Per Share (Diluted) of $0.04 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-07-30
- VERICEL CORPORATION earnings per share, diluted for the quarter ending 2026-06-30 was $0.04.
- VERICEL CORPORATION earnings per share, diluted for the quarter ending 2026-03-31 was -$0.12.
- VERICEL CORPORATION earnings per share, diluted for the quarter ending 2025-12-31 was $0.40, a 23.36% increase year-over-year.
- VERICEL CORPORATION earnings per share, diluted for the quarter ending 2025-09-30 was $0.10.
- VERICEL CORPORATION earnings per share, diluted for fiscal 2025 was $0.32, a 60.00% increase from fiscal 2024.
- VERICEL CORPORATION earnings per share, diluted for fiscal 2024 was $0.20.
- VERICEL CORPORATION earnings per share, diluted for fiscal 2023 was -$0.07.
- VERICEL CORPORATION earnings per share, diluted for fiscal 2022 was -$0.35.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.04 10-Q · filed 2026-07-30 | -$0.08 10-Q · filed 2026-07-30 | $0.36 derived: net income ÷ weighted average shares · filed 2026-07-30 | $0.46 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2026-03-31 | -$0.12 10-Q · filed 2026-05-07 | $0.31 derived: net income ÷ weighted average shares · filed 2026-07-30 | $0.41 derived: net income ÷ weighted average shares · filed 2026-07-30 | $0.41 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2025-12-31 | $0.40 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.52 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.52 derived: net income ÷ weighted average shares · filed 2026-07-30 | $0.32 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.10 10-Q · filed 2025-11-06 | $0.09 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$0.13 10-Q · filed 2025-11-06 | $0.25 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2025-06-30 | -$0.01 10-Q · filed 2026-07-30 | -$0.24 10-Q · filed 2026-07-30 | $0.15 derived: net income ÷ weighted average shares · filed 2026-07-30 | $0.14 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2025-03-31 | -$0.23 10-Q · filed 2026-05-07 | $0.15 derived: net income ÷ weighted average shares · filed 2026-07-30 | $0.14 derived: net income ÷ weighted average shares · filed 2026-07-30 | $0.06 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2024-12-31 | $0.33 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.34 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.27 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.20 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.02 10-Q · filed 2025-11-06 | -$0.11 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.19 10-Q · filed 2025-11-06 | $0.07 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-06-30 | -$0.10 10-Q · filed 2025-07-31 | -$0.18 10-Q · filed 2025-07-31 | $0.09 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.02 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-03-31 | -$0.08 10-Q · filed 2025-05-08 | $0.19 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.11 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.01 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2023-12-31 | $0.27 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.20 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.09 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.07 10-K · filed 2026-02-26 |
| 2023-09-30 | -$0.08 10-Q · filed 2024-11-07 | -$0.18 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$0.34 10-Q · filed 2024-11-07 | -$0.22 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-06-30 | -$0.11 10-Q · filed 2024-08-01 | -$0.26 10-Q · filed 2024-08-01 | -$0.14 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.28 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-03-31 | -$0.16 10-Q · filed 2024-05-08 | -$0.03 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.17 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.36 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2022-12-31 | $0.13 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.01 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.20 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.35 10-K · filed 2025-02-27 |
| 2022-09-30 | -$0.14 10-Q · filed 2023-11-08 | -$0.33 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$0.48 10-Q · filed 2023-11-08 | -$0.38 derived: net income ÷ weighted average shares · filed 2024-02-29 |
| 2022-06-30 | -$0.19 10-Q · filed 2023-08-02 | -$0.34 10-Q · filed 2023-08-02 | -$0.25 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$0.35 derived: net income ÷ weighted average shares · filed 2024-02-29 |
| 2022-03-31 | -$0.15 10-Q · filed 2023-05-10 | -$0.05 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$0.16 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$0.24 derived: net income ÷ weighted average shares · filed 2024-02-29 |
| 2021-12-31 | $0.10 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$0.01 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$0.09 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$0.16 10-K · filed 2024-02-29 |
| 2021-09-30 | -$0.11 10-Q · filed 2022-11-09 | -$0.19 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$0.26 10-Q · filed 2022-11-09 | $0.00 derived: net income ÷ weighted average shares · filed 2023-02-23 |
| 2021-06-30 | -$0.08 10-Q · filed 2022-08-03 | -$0.15 10-Q · filed 2022-08-03 | $0.11 derived: net income ÷ weighted average shares · filed 2023-02-23 | $0.18 derived: net income ÷ weighted average shares · filed 2023-02-23 |
| 2021-03-31 | -$0.07 10-Q · filed 2022-05-04 | $0.18 derived: net income ÷ weighted average shares · filed 2023-02-23 | $0.26 derived: net income ÷ weighted average shares · filed 2023-02-23 | $0.09 derived: net income ÷ weighted average shares · filed 2023-02-23 |
| 2020-12-31 | $0.25 10-K · filed 2021-02-24 | $0.31 derived: net income ÷ weighted average shares · filed 2023-02-23 | $0.16 derived: net income ÷ weighted average shares · filed 2023-02-23 | $0.06 10-K · filed 2023-02-23 |
| 2020-09-30 | $0.08 10-Q · filed 2021-11-09 | -$0.10 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$0.21 10-Q · filed 2021-11-09 | $0.00 derived: net income ÷ weighted average shares · filed 2022-02-24 |
| 2020-06-30 | -$0.18 10-Q · filed 2021-08-04 | -$0.29 10-Q · filed 2021-08-04 | -$0.08 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$0.00 derived: net income ÷ weighted average shares · filed 2022-02-24 |
| 2020-03-31 | -$0.10 10-Q · filed 2021-05-05 | $0.11 derived: net income ÷ weighted average shares · filed 2022-02-24 | $0.18 derived: net income ÷ weighted average shares · filed 2022-02-24 | |
| 2019-12-31 | $0.20 10-K · filed 2021-02-24 | $0.28 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$0.22 10-K · filed 2022-02-24 | |
| 2019-09-30 | $0.07 10-K · filed 2021-02-24 | -$0.44 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | -$0.45 10-K · filed 2021-02-24 | |||
| 2019-03-31 | -$0.07 10-K · filed 2021-02-24 | |||
| 2018-12-31 | $0.11 10-K · filed 2020-02-25 | $0.10 derived: net income ÷ weighted average shares · filed 2021-02-24 | -$0.20 10-K · filed 2021-02-24 | |
| 2018-09-30 | -$0.02 10-K · filed 2020-02-25 | -$0.34 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | -$0.12 10-K · filed 2020-02-25 | |||
| 2018-03-31 | -$0.21 10-K · filed 2020-02-25 | |||
| 2012-03-31 | -$0.24 derived: net income ÷ weighted average shares · filed 2013-05-08 | -$0.32 derived: net income ÷ weighted average shares · filed 2014-03-13 | -$0.37 derived: net income ÷ weighted average shares · filed 2014-03-13 | -$0.62 derived: net income ÷ weighted average shares · filed 2014-03-13 |
| 2011-12-31 | -$0.07 derived: net income ÷ weighted average shares · filed 2014-03-13 | -$0.12 derived: net income ÷ weighted average shares · filed 2014-03-13 | -$0.38 derived: net income ÷ weighted average shares · filed 2014-03-13 | -$0.51 derived: net income ÷ weighted average shares · filed 2014-03-13 |
| 2011-09-30 | -$0.05 derived: net income ÷ weighted average shares · filed 2012-11-08 | -$0.31 derived: net income ÷ weighted average shares · filed 2012-11-08 | -$0.44 derived: net income ÷ weighted average shares · filed 2012-11-08 | |
| 2011-06-30 | -$0.26 derived: net income ÷ weighted average shares · filed 2012-08-07 | -$0.39 derived: net income ÷ weighted average shares · filed 2012-08-07 | ||
| 2011-03-31 | -$0.13 derived: net income ÷ weighted average shares · filed 2012-05-10 | |||
| 2010-12-31 | -$0.65 derived: net income ÷ weighted average shares · filed 2013-03-18 | |||
| 2010-06-30 | -$0.59 derived: net income ÷ weighted average shares · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |